Clinical value of the <i>MGMT</i> promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment

While the <i>MGMTp</i> methylation score was associated with better outcomes in TMZ-treated IDHmt LGG, a cutoff could not be established to guide treatment decisions.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology Advances
Published
2024-12-19
DOI
https://doi.org/10.1093/noajnl/vdae224
Citations
3
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment

Karine Lefort, Amélie Darlix, Emmanuelle Le Bars, Arthur Coget et al.
3 citations
Neuro-Oncology Advances
Glioma Diagnosis and Treatment
1.31
article

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment

Karine Lefort, Amélie Darlix, Emmanuelle Le Bars, Arthur Coget, Tomasz Matys, Mathilde Carrière, Monika E. Hegi, Valérie Rigau, Jérémy Deverdun, Thomas Santarius, Pierre Bady, Hugues Duffau
article en
3 citations

Abstract

While the <i>MGMTp</i> methylation score was associated with better outcomes in TMZ-treated IDHmt LGG, a cutoff could not be established to guide treatment decisions.

Neuro-Oncology AdvancesVol. 7(1)
SIB Swiss Institute of Bioinformatics (CH), Centre National de la Recherche Scientifique (FR), Inserm (FR), Université de Montpellier (FR), University of Cambridge (GB), Cambridge University Hospitals NHS Foundation Trust (GB), University Medical Center (US), University Hospital and Clinics (US), Hôpital Gui de Chauliac (FR), Institut de Recherche en Cancérologie de Montpellier (FR), Institut de Génomique Fonctionnelle (FR), University of Lausanne (CH)
National Science Foundation, National Institute for Health and Care Research, University of Cambridge, Institut National de la Santé et de la Recherche Médicale, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Brain Tumour Charity, Cambridge University Hospitals, Centre National de la Recherche Scientifique, Université de Lausanne, Centre Hospitalier Universitaire Vaudois, Université de Montpellier, Swiss Cancer Research Foundation, Swiss Institute of Bioinformatics, NIHR Cambridge Biomedical Research Centre
Good health and well-being
Openalex Percentile: Top 17%
Glioma Diagnosis and Treatment
1.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.